A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Clinical trial NCT05378425 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05378425
Sponsor: Nectin Therapeutics Ltd
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Cancer Tumor, Solid Advanced Solid Tumor Metastatic Cancer Locally Advanced Solid Tumor

Start date: 2022-09-01
Primary completion: 2026-12-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.